The primary challenge with combining next-gen KRAS inhibitors and immunotherapy is a rapid and severe liver toxicity (transaminitis). A patient's liver function can deteriorate catastrophically in days, demanding vigilant monitoring and specific management protocols that differ between clinical trials.

The primary challenge in combining KRAS inhibitors with immunotherapy is managing toxicity. A severe side effect could force discontinuation of both drugs, thereby sacrificing the potential for a long-term cure from immunotherapy alone. The goal is to avoid trading overall survival for a higher initial response rate.

While neoadjuvant pembrolizumab (KEYNOTE-689) is now standard of care for resectable head and neck cancer, it carries a critical risk. During the pre-surgical treatment window, some patients may experience disease progression or toxicity that makes them ineligible for their planned curative surgery.

While pan-RAS inhibitors like daroxiracib can target multiple mutations, they cause significantly more GI and skin toxicity. For a homogenous KRAS G12C mutation, a mutant-selective inhibitor is preferred as it offers comparable efficacy with a much more manageable side effect profile, crucial for maintaining dose intensity.

While neoadjuvant-only immunotherapy has a strong rationale, a patient-level cross-trial comparison of CheckMate 816 (neoadjuvant) and 770T (perioperative) suggests the addition of adjuvant therapy improves event-free survival, favoring a full perioperative approach.

The distinct side effect profiles of pan-RAS inhibitors (rash, mucositis) and G12D-specific inhibitors (GI issues) are driving separate clinical strategies. The G12D drugs' better combinability with chemotherapy contrasts with pan-RAS agents, which may be better suited for monotherapy due to toxicity from blocking normal RAS.

Combining KRAS G12C inhibitors with checkpoint inhibitors increases the risk of transaminitis. Differentiating the causative agent is clinically challenging. A rapid recovery after stopping both drugs suggests the KRAS inhibitor is the cause and can be restarted at a lower dose; slower recovery points to the immunotherapy.

The combination of the KRAS G12C inhibitor Sotorasib with immunotherapy, a seemingly logical approach, has been abandoned. Clinical trials were closed due to unacceptable levels of hepatotoxicity (liver damage), particularly in patients who had recently received immunotherapy. This demonstrates an unexpected and clinically significant negative drug-drug interaction, serving as a cautionary tale for future combination studies.

While the avutometanib/defactinib combination is newly approved for KRAS-mutated ovarian cancer, its significant toxicity profile—causing up to a third of patients to stop treatment—creates a clear clinical need for agents like specific KRAS inhibitors that may offer similar efficacy with better tolerability.